Triera Biosciences

Triera Biosciences Logo

Unlocking the Potential of Aptamers

About Triera Biosciences

Driven to Surpass What’s Possible

At Triera Biosciences, the pursuit of innovation is deeply intertwined with a commitment to real-world impact. Our team, comprised of leading scientists and experts across academia and business, collaborates with private and public sectors to advance the field of aptamer research. Our ultimate goal is far more than academic or even scientific: it’s profoundly human.

"I am convinced that this aptamer and delivery system have immense potential to transform prevention and treatments of SARS-CoV-2."

Matthew Miller, Associate Professor, Department of Biochemistry and Biomedical Sciences, McMaster University

This unwavering commitment to improving people’s lives is what sets Triera Biosciences apart, positioning us at the thrilling intersection of scientific excellence and human potential.

Triera Biosciences and McMaster University

Triera Biosciences has partnered with McMaster University in an exclusive, worldwide agreement to develop aptamer therapeutic platforms for the next 20 years. Our combined expertise and mutual capabilities offer significant advantages in the development process, including:

Significantly Reduced Cost

New drug development through preclinical costs on average between $200-$250M USD. McMaster University’s existing internal resources and facilities dramatically lower these costs.

Greatly Improved Speed

Broad applicability and process of aptamer development for new therapeutic targets allows us to reach clinical trials a lot faster than industry average.

Key Personnel

McMaster University

Dr. Yingfu Li

Professor, Department of Biochemistry & Biomedical Sciences

Dr. Li earned a Ph.D. in Biochemistry from Simon Fraser University, and has earned many accolades in his career since: Governor General Academic Gold Medal, Engineering Research Council of Canada Doctoral Prize, and awarded postdoctoral fellow of the Medical Research Council of Canada. Following notable postdoctoral studies at Yale University, his research at McMaster has focused on aptamers and DNAzymes, where he has gained a global reputation as a leader in the field.​

Dr. Matthew Miller

Associate Professor, Department of Biochemistry & Biomedical Sciences

Dr. Miller completed his PhD at the University of Western Ontario studying the molecular virology of DNA viruses, and then conducted postdoctoral research at the Icahn School of Medicine focusing on characterizing the innate and adaptive immune responses to viral infection. His innovative and groundbreaking work has been instrumental in the ongoing development of a ‘universal’ influenza virus vaccine.

Triera Biosciences

Greg Fenton

Director and Interim CEO, Triera Biosciences

Greg Fenton is a seasoned investment professional with a Bay Street career spanning nearly 30 years, including work in various capacities with ever-increasing responsibility in both the Canadian banking and investment management sectors. His experience spans many disciplines: capital markets, investment management, actuarial, pension, insurance, accounting, tax, and risk management.​

Dr. Colin van der Kuur

CSO, Triera Biosciences

Dr. van der Kuur was the first graduate from University of Guelph with a Specialized Honours in Chemical Physics in 1993, and subsequently completed a doctorate in leadership in 2010. Through his leadership, Zentek is rapidly expanding a high-value IP portfolio through internal research, collaboration, and licensing world-leading technology.

John Snisarenko

Advisory Board Member, Triera Biosciences
John Snisarenko brings with him 35 years of specialty pharmaceutical, medical device and commercialization experience spanning from start-up to large pharmaceutical and biotech companies, including 15 years in the United States in executive positions with Genentech and Shire. He was also a key member of the Genentech/Novartis Global Alliance Partnership for Lucentis in ophthalmology. Currently, he serves as an Independent Director, Board Member, and Advisor to numerous companies.

John holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.

Zentek Ltd.: Improving Lives Through Nanotechnology

Triera Biosciences is a wholly owned subsidiary of Zentek Ltd., an IP development and commercialization company harnessing the power of cutting-edge technologies including nanomaterials and graphene. Zentek and Triera Biosciences share the same guiding mission: developing innovative new solutions that quantifiably improve people’s lives on multiple fronts.